Cancer Targeted Technology is designing and patenting small molecular weight enzyme inhibitors with unique and exceptional imaging and drug delivery properties.
June 29, 2021
Cancer Targeted Technology Receives Milestone Payment for Development of Diagnostic PET Imaging Agent for Prostate Cancer
August 7, 2020
NIH grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403